Qiagen (QGEN.BRN) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

QGEN.BRN Analyst Ratings

Moderate Buy

5 Buy

7 Hold

0 Sell

Based on 12 analysts giving stock ratings to

Qiagen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

QGEN.BRN Stock 12 Month Forecast

Average Price Target

CHF35.41

▼(-29.69% Downside)

Based on 12 Wall Street analysts offering 12 month price targets for Qiagen in the last 3 months. The average price target is CHF35.41 with a high forecast of CHF40.52 and a low forecast of CHF31.28. The average price target represents a -29.69% change from the last price of CHF50.36.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"CHF30","51":"CHF51","35.25":"CHF35.3","40.5":"CHF40.5","45.75":"CHF45.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40.5202475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF40.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35.40979741707725,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF35.41</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.281631070000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF31.28</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,35.25,40.5,45.75,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.36,49.603095961538465,48.84619192307692,48.08928788461539,47.332383846153846,46.57547980769231,45.81857576923077,45.061671730769234,44.30476769230769,43.54786365384616,42.790959615384615,42.03405557692308,41.27715153846154,{"y":40.5202475,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.36,49.20998441669825,48.059968833396496,46.90995325009475,45.759937666793,44.60992208349125,43.4599065001895,42.30989091688775,41.159875333586,40.00985975028425,38.8598441669825,37.709828583680746,36.559813000378995,{"y":35.40979741707725,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,50.36,48.89243315923077,47.42486631846154,45.95729947769231,44.48973263692308,43.02216579615385,41.55459895538462,40.08703211461538,38.61946527384616,37.15189843307692,35.6843315923077,34.21676475153846,32.74919791076923,{"y":31.281631070000003,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":50.36,"date":1756674000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1759266000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1761948000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1764540000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1767218400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1769896800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1772316000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1774990800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1777582800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1780261200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1782853200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.36,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF40.52

Average Price TargetCHF35.41

Lowest Price TargetCHF31.28

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Larew

William Blair

―

Hold

―

Assigned

08/24/26

Qiagen: CEO Appointment and Strategic Review Temper Takeover Hopes, Justifying Hold Rating on Valuation

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Buy

―

Reiterated

08/12/26

DZ BANK AG Reaffirms Their Buy Rating on Qiagen (QGEN)

Daniel Arias

Stifel Nicolaus

CHF32.42

Hold

-35.63%

Downside

Reiterated

08/11/26

Stifel Nicolaus Sticks to Their Hold Rating for Qiagen (QGEN)

Casey Woodring

J.P. Morgan

CHF40.52

Buy

-19.54%

Downside

Reiterated

08/10/26

Analysts' Top Healthcare Picks: Qiagen (QGEN), Establishment Labs Holdings (ESTA)

‏Brendan Digan‏

Citi

CHF30.8→CHF36.47

Hold

-27.58%

Downside

Reiterated

08/10/26

Qiagen price target raised to $45 from $38 at CitiQiagen price target raised to $45 from $38 at Citi

Jan Koch

Deutsche Bank

―

Buy

―

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Claritev (NYSE: CTEV) and Qiagen (NYSE: QGEN)

Luke Sergott

Barclays

CHF30.8→CHF32.42

Hold

-35.63%

Downside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Protagonist Therapeutics (NASDAQ: PTGX), Qiagen (NYSE: QGEN) and Envista Holdings (NYSE: NVST)

Aisyah Noor

Morgan Stanley

CHF34.82→CHF37.64

Buy

-25.25%

Downside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)

Tycho Peterson

Jefferies

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Qiagen (NYSE: QGEN) and Coherus Biosciences (NASDAQ: CHRS)

Harry Gillis

Berenberg Bank

CHF36.87

Hold

-26.78%

Downside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Qiagen (NYSE: QGEN) and Sanofi (Other OTC: SNYNF)

Daniel Brennan

TD Cowen

CHF32.42→CHF35.66

Hold

-29.19%

Downside

Reiterated

07/15/26

Qiagen price target raised to $44 from $40 at TD CowenQiagen price target raised to $44 from $40 at TD Cowen

Unknown Analyst

Kepler Capital

Not Ranked

Kepler Capital

CHF31.28

Hold

-37.88%

Downside

Initiated

06/25/26

Qiagen (QGEN) Gets a Hold from Kepler Capital

Michael Ryskin

Bank of America Securities

CHF39.71

Buy

-21.15%

Downside

Reiterated

05/13/26

Analysts Conflicted on These Healthcare Names: Qiagen (NYSE: QGEN), SAB Biotherapeutics (NASDAQ: SABS) and Moderna (NASDAQ: MRNA)

Catherine Ramsey Schulte

Robert W. Baird

CHF42.95→CHF34.85

Buy

-30.80%

Downside

Upgraded

04/29/26

Qiagen upgraded to Outperform from Neutral at BairdQiagen upgraded to Outperform from Neutral at Baird

Dan Leonard

RBC Capital

CHF42.14

Hold

-16.32%

Downside

Reiterated

02/09/26

Qiagen: Slower Core Growth and Back-Half-Loaded Targets Keep Risk/Reward Balanced at Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Larew

William Blair

―

Hold

―

Assigned

08/24/26

Qiagen: CEO Appointment and Strategic Review Temper Takeover Hopes, Justifying Hold Rating on Valuation

Unknown Analyst

DZ BANK AG

Not Ranked

DZ BANK AG

―

Buy

―

Reiterated

08/12/26

DZ BANK AG Reaffirms Their Buy Rating on Qiagen (QGEN)

Daniel Arias

Stifel Nicolaus

CHF32.42

Hold

-35.63%

Downside

Reiterated

08/11/26

Stifel Nicolaus Sticks to Their Hold Rating for Qiagen (QGEN)

Casey Woodring

J.P. Morgan

CHF40.52

Buy

-19.54%

Downside

Reiterated

08/10/26

Analysts' Top Healthcare Picks: Qiagen (QGEN), Establishment Labs Holdings (ESTA)

‏Brendan Digan‏

Citi

CHF30.8→CHF36.47

Hold

-27.58%

Downside

Reiterated

08/10/26

Qiagen price target raised to $45 from $38 at CitiQiagen price target raised to $45 from $38 at Citi

Jan Koch

Deutsche Bank

―

Buy

―

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Claritev (NYSE: CTEV) and Qiagen (NYSE: QGEN)

Luke Sergott

Barclays

CHF30.8→CHF32.42

Hold

-35.63%

Downside

Reiterated

08/07/26

Analysts Conflicted on These Healthcare Names: Protagonist Therapeutics (NASDAQ: PTGX), Qiagen (NYSE: QGEN) and Envista Holdings (NYSE: NVST)

Aisyah Noor

Morgan Stanley

CHF34.82→CHF37.64

Buy

-25.25%

Downside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM) and Qiagen (NYSE: QGEN)

Tycho Peterson

Jefferies

―

Buy

―

Reiterated

08/06/26

Analysts Offer Insights on Healthcare Companies: Agilon Health (NYSE: AGL), Qiagen (NYSE: QGEN) and Coherus Biosciences (NASDAQ: CHRS)

Harry Gillis

Berenberg Bank

CHF36.87

Hold

-26.78%

Downside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Qiagen (NYSE: QGEN) and Sanofi (Other OTC: SNYNF)

Daniel Brennan

TD Cowen

CHF32.42→CHF35.66

Hold

-29.19%

Downside

Reiterated

07/15/26

Qiagen price target raised to $44 from $40 at TD CowenQiagen price target raised to $44 from $40 at TD Cowen

Unknown Analyst

Kepler Capital

Not Ranked

Kepler Capital

CHF31.28

Hold

-37.88%

Downside

Initiated

06/25/26

Qiagen (QGEN) Gets a Hold from Kepler Capital

Michael Ryskin

Bank of America Securities

CHF39.71

Buy

-21.15%

Downside

Reiterated

05/13/26

Analysts Conflicted on These Healthcare Names: Qiagen (NYSE: QGEN), SAB Biotherapeutics (NASDAQ: SABS) and Moderna (NASDAQ: MRNA)

Catherine Ramsey Schulte

Robert W. Baird

CHF42.95→CHF34.85

Buy

-30.80%

Downside

Upgraded

04/29/26

Qiagen upgraded to Outperform from Neutral at BairdQiagen upgraded to Outperform from Neutral at Baird

Dan Leonard

RBC Capital

CHF42.14

Hold

-16.32%

Downside

Reiterated

02/09/26

Qiagen: Slower Core Growth and Back-Half-Loaded Targets Keep Risk/Reward Balanced at Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

PTGXProtagonist Therapeutics

AXGNAxoGen

ATECAlphatec Holdings

CABACabaletta Bio

ONCBeOne Medicines

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Qiagen

3 Months

Jan KochDeutsche Bank

Success Rate

7/10 ratings generated profit

Average Return

+9.78%

Copying Jan Koch's trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +9.78% per trade.

1 Year

Jan KochDeutsche Bank

Success Rate

10/10 ratings generated profit

Average Return

+19.26%

Copying Jan Koch's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +19.26% per trade.

2 Years

Jan KochDeutsche Bank

Success Rate

10/10 ratings generated profit

Average Return

+19.26%

Copying Jan Koch's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +19.26% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

QGEN.BRN Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, QGEN.BRN has received 8 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. QGEN.BRN average Analyst price target in the past 3 months is 35.41.

Each month's total comprises the sum of three months' worth of ratings.

QGEN.BRN Financial Forecast

QGEN.BRN Earnings Forecast

Next quarter’s earnings estimate for QGEN.BRN is CHF0.50 with a range of CHF0.49 to CHF0.51. The previous quarter’s EPS was CHF0.50. QGEN.BRN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year QGEN.BRN has Performed in-line its overall industry.

QGEN.BRN Sales Forecast

Next quarter’s sales forecast for QGEN.BRN is CHF436.24M with a range of CHF432.28M to CHF438.24M. The previous quarter’s sales results were CHF435.57M. QGEN.BRN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year QGEN.BRN has Performed in-line its overall industry.

QGEN.BRN Stock Forecast FAQ

What is CH:QGEN.BRN’s average 12-month price target, according to analysts?

Based on analyst ratings, Qiagen NV’s 12-month average price target is 35.41.

What is CH:QGEN.BRN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for CH:QGEN.BRN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Qiagen NV a Buy, Sell or Hold?

Qiagen NV has a consensus rating of Moderate Buy, which is based on 5 buy ratings, 7 hold ratings and 0 sell ratings.

What is Qiagen NV’s share price target?

The average share price target for Qiagen NV is 35.41. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF40.52 ,and the lowest forecast is CHF31.28. The average share price target represents -29.69% Decrease from the current price of CHF50.36.

What do analysts say about Qiagen NV?

Qiagen NV’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of Qiagen NV?

To buy shares of CH:QGEN.BRN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Qiagen (QGEN.BRN) Stock Forecast & Price Target

QGEN.BRN Analyst Ratings

QGEN.BRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Qiagen

QGEN.BRN Analyst Recommendation Trends

QGEN.BRN Financial Forecast

QGEN.BRN Earnings Forecast

QGEN.BRN Sales Forecast

QGEN.BRN Stock Forecast FAQ

Detailed List of Analyst Forecasts